MaxCyte Inc. (MXCT)
MXCT trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1287098/000110465926034557/0001104659-26-034557-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MXCT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001287098 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $33.0M |
| Net income | -$44.6M |
| Operating income | -$51.9M |
| Net margin | -135.1% |
| Operating margin | -157.1% |
| Revenue growth | -14.5% |
| Cash | $20.1M |
| Total assets | $202.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $13.4M cash; operating cash flow -$5.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 103,250,292 (2026-11-06); 106,674,011 a year earlier; 103,576,429 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-03-20 |
| Auditor | CohnReznick LLP, Tysons, Virginia, United States | PCAOB Form AP 2026-04-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $8K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $10.2M | -$4.8M | -$5.5M | $13.4M | No debt tags | $34.4M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $7.3M | -$8.9M | -$4.7M | $15.0M | No debt tags | $31.1M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $9.7M | -$4.8M | -$8.2M | $14.6M | No debt tags | $32.3M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $7.3M | -$9.6M | -$2.7M | $20.1M | No debt tags | $33.0M | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | $6.8M | -$12.4M | -$7.5M | $13.0M | No debt tags | $34.4M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $8.5M | -$12.4M | -$9.9M | $15.2M | No debt tags | $35.8M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $10.4M | -$10.3M | -$14.4M | $23.4M | No debt tags | $37.7M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $8.7M | -$10.6M | -$7.8M | $27.9M | No debt tags | $38.6M | 10-K 2026-03-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2021-07-30 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report FORM 8-K | 8-K | 2026-11-10 |
| Latest proxy DEFA 14A | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 338 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.6% |
| 1 month | +23.4% |
| 3 months | -14.4% |
| Year to date | -23.2% |
| 1 year | -21.2% |
| From 52-week high | -32.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ONMD | OneMedNet Corp | $4.86 | -8.99% | $29.2M |
| NRC | NRC Health | $26.33 | -0.87% | $558.8M |
| OABI | OmniAb Inc. | $4.89 | -0.41% | $713.3M |
| ABSI | Absci Corporation | $7.47 | -11.54% | $1.3B |
| BIAF | bioAffinity Technologies Inc. | $2.00 | -9.09% | $3.6M |
| ISPC | iSpecimen Inc. | $0.6049 | -8.17% | $3.3M |
| ICLR | ICON plc | $191.40 | -1.67% | $14.7B |
| CRL | Charles River Laboratories International Inc. | $335.52 | -0.72% | $16.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier